Welcome to our dedicated page for Vext Science news (Ticker: VEXTF), a resource for investors and traders seeking the latest updates and insights on Vext Science stock.
Vext Science, Inc. (VEXTF) is a vertically integrated U.S. cannabis operator with cultivation, manufacturing, and retail operations in Arizona and Ohio. This page provides investors and industry observers with direct access to official company announcements, including earnings reports, regulatory updates, and strategic initiatives.
Track Vext Science's progress through press releases detailing operational expansions, product innovations under its Vapen brand, and compliance milestones in medical and adult-use markets. Our curated collection ensures timely access to material developments affecting the company's position as a leader in THC concentrate production and cost-efficient facility build-outs.
Key updates include manufacturing advancements, retail dispensary openings, licensing achievements, and financial performance. Bookmark this page to monitor how Vext Science leverages its fully integrated model to maintain quality control across its supply chain while adapting to evolving cannabis regulations.
Vext Science (OTCQX: VEXTF), a U.S.-based cannabis operator with operations in Arizona and Ohio, has scheduled the release of its Q1 2025 financial results for May 21, 2025, before market open. The company will host a conference call and webcast on the same day at 8:00 AM ET to discuss the results.
Interested participants can join via phone using the dial-in numbers +1-647-849-3159 or 1-833-752-3966 (Conference ID: 10199977). A replay will be available until June 4, 2025, using playback number 5885585. The webcast can be accessed at www.gowebcasting.com/14070, and a replay will be available on Vext's investor website after the call.
Vext Science (VEXTF) has announced the strategic sale of its Kentucky medical cannabis processing license for US$880,000 through its subsidiary Vapen Kentucky. The transaction aligns with the company's focused approach on its core markets in Arizona and Ohio.
Prior to the sale, on March 16, 2025, Vext acquired the remaining 50% membership interest in Vapen Kentucky from its joint venture partner using non-cash consideration. Following the transaction's closure, Vapen Kentucky will redirect its focus to hemp-related business opportunities.
The proceeds will be allocated towards:
- Repayment of existing credit facilities
- Development of Ohio retail footprint
- General corporate purposes
Vext Science (VEXTF) has completed the acquisition of two cannabis dispensaries from Big Perm's Dispensary Ohio for US$8.1 million, doubling its retail presence in Ohio. The acquisition adds locations in Athens and Jeffersonville to existing dispensaries in Jackson and Columbus.
The company is now fully vertically integrated in Ohio with:
- A Tier I cultivation facility (25,000 sq ft, expandable to 50,000 sq ft)
- A manufacturing facility
- Four operational medical and adult-use dispensaries
Vext has secured approval to develop three additional dual-use dispensaries and expects its Portsmouth location to commence operations in Q2/Q3 2025. The company is on track to reach Ohio's state license cap of eight dispensaries by early 2026, with cash flow projected to return to growth in Q4 2024.
Vext Science (VEXTF) reported strong Q4 2024 financial results, marking its strongest operating quarter in recent years. Revenue reached $10.2 million in Q4 2024, up 13% quarter-over-quarter, driven by Ohio adult-use sales and Arizona operations. Adjusted EBITDA grew significantly to $3.2 million (compared to $0.5 million in Q4 2023), while cash flow from operations turned positive at $4 million.
The company received approval from Ohio's Division of Cannabis Control to acquire Big Perm dispensaries in Athens and Jeffersonville. This expansion will double Vext's Ohio retail footprint to four locations. Additionally, Vext secured a provisional license for a fifth dispensary in Portsmouth, Ohio, expected to open in Q2/Q3 2025. The company aims to reach Ohio's dispensary license cap of eight locations by early 2026.
In Arizona, despite a 25% decline in statewide per-store sales, Vext maintained market share through effective retail traffic management and improved yields at its Eloy cultivation facility.
Vext Science (CSE: VEXT, OTCQX: VEXTF), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, has scheduled its Q4 and fiscal 2024 financial results announcement for March 31, 2025, before market open.
The company will host a conference call and webcast on the same day at 8:00 AM ET to discuss the quarterly and full-year 2024 results. Participants can join via phone using dial-in numbers +1-647-849-3159 or 1-833-752-3966 (Conference ID: 10197749). A replay will be available until April 14, 2025, using playback number 5786741.
Vext Science (VEXTF) has relocated and expanded its Herbal Wellness Center dispensary in Jackson, Ohio, doubling its retail footprint. The new location features an 8,350 square foot space, including 4,500 square feet for retail operations and a drive-thru window for improved customer convenience.
The company operates a vertically integrated business in Ohio, including a Tier I cultivation facility, a manufacturing facility, and two operational dispensaries in Jackson and Columbus. Vext is pursuing expansion to reach Ohio's maximum limit of eight dispensaries, with plans to add locations in Athens, Jeffersonville, and Portsmouth through its Ohio Expansion Transaction, expected to close in Q1 2025.
The company has received approval to develop three additional dual-use dispensaries under the DCC's 10(B) license program. The new Jackson location is leased with a purchase option, offering flexibility for future growth and potential sublease opportunities to offset occupancy costs.
Vext Science (CSE: VEXT, OTCQX: VEXTF), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, announced the voting results from its annual general meeting held on December 13, 2024, in Vancouver. Shareholders demonstrated strong support for all matters presented in the management information circular, with each resolution passing with over 98% approval. The voting represented 73.45% of the total issued and outstanding shares of the company.
FAQ
What is the current stock price of Vext Science (VEXTF)?
What is the market cap of Vext Science (VEXTF)?
